Krishna Institute of Medical Sciences Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Krishna Institute of Medical Sciences wird ein jährliches Gewinn- und Umsatzwachstum von 24.7% bzw. 22.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 1.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.3% betragen.
Wichtige Informationen
24.7%
Wachstumsrate der Gewinne
1.7%
EPS-Wachstumsrate
Healthcare Gewinnwachstum | 27.5% |
Wachstumsrate der Einnahmen | 22.2% |
Zukünftige Eigenkapitalrendite | 19.3% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 12 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Krishna Institute of Medical Sciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 13Krishna Institute of Medical Sciences Limited (NSE:KIMS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 10Krishna Institute of Medical Sciences Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 08Recent updates
Krishna Institute of Medical Sciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 13There's Reason For Concern Over Krishna Institute of Medical Sciences Limited's (NSE:KIMS) Massive 26% Price Jump
Sep 05We Think The Compensation For Krishna Institute of Medical Sciences Limited's (NSE:KIMS) CEO Looks About Right
Aug 23Krishna Institute of Medical Sciences Limited (NSE:KIMS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 10Is Krishna Institute of Medical Sciences (NSE:KIMS) Using Too Much Debt?
Jul 02Krishna Institute of Medical Sciences Limited's (NSE:KIMS) Shares May Have Run Too Fast Too Soon
Jun 12Is Now The Time To Put Krishna Institute of Medical Sciences (NSE:KIMS) On Your Watchlist?
Apr 28We Like These Underlying Return On Capital Trends At Krishna Institute of Medical Sciences (NSE:KIMS)
Apr 10Risks To Shareholder Returns Are Elevated At These Prices For Krishna Institute of Medical Sciences Limited (NSE:KIMS)
Feb 29Krishna Institute of Medical Sciences Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 08Krishna Institute of Medical Sciences Limited (NSE:KIMS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Jan 23Investors Will Want Krishna Institute of Medical Sciences' (NSE:KIMS) Growth In ROCE To Persist
Nov 21Do Krishna Institute of Medical Sciences' (NSE:KIMS) Earnings Warrant Your Attention?
Aug 23Returns Are Gaining Momentum At Krishna Institute of Medical Sciences (NSE:KIMS)
Aug 02Krishna Institute of Medical Sciences' (NSE:KIMS) Returns On Capital Are Heading Higher
Apr 01Krishna Institute of Medical Sciences (NSE:KIMS) Is Looking To Continue Growing Its Returns On Capital
Dec 14Analysts Have Made A Financial Statement On Krishna Institute of Medical Sciences Limited's (NSE:KIMS) First-Quarter Report
Aug 13Krishna Institute of Medical Sciences (NSE:KIMS) Is Investing Its Capital With Increasing Efficiency
Aug 12Here's Why Krishna Institute of Medical Sciences (NSE:KIMS) Has Caught The Eye Of Investors
Jul 02Krishna Institute of Medical Sciences Limited (NSE:KIMS) Investors Are Less Pessimistic Than Expected
May 08Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
3/31/2027 | 47,176 | 6,287 | 3,836 | 9,626 | 9 |
3/31/2026 | 37,985 | 4,673 | 2,720 | 7,564 | 13 |
3/31/2025 | 30,701 | 3,889 | -2,967 | 6,423 | 11 |
9/30/2024 | 27,053 | 3,313 | -2,409 | 4,964 | N/A |
6/30/2024 | 25,805 | 3,159 | N/A | N/A | N/A |
3/31/2024 | 24,981 | 3,101 | -1,262 | 5,211 | N/A |
12/31/2023 | 24,403 | 3,379 | N/A | N/A | N/A |
9/30/2023 | 23,966 | 3,421 | -2,263 | 4,621 | N/A |
6/30/2023 | 23,082 | 3,472 | N/A | N/A | N/A |
3/31/2023 | 21,977 | 3,363 | -1,424 | 4,321 | N/A |
12/31/2022 | 19,941 | 3,237 | N/A | N/A | N/A |
9/30/2022 | 18,255 | 3,289 | 741 | 3,693 | N/A |
6/30/2022 | 16,732 | 3,135 | N/A | N/A | N/A |
3/31/2022 | 16,508 | 3,327 | 1,537 | 3,240 | N/A |
12/31/2021 | 16,370 | 3,098 | N/A | N/A | N/A |
9/30/2021 | 16,041 | 2,774 | 2,318 | 3,488 | N/A |
6/30/2021 | 16,020 | 2,792 | N/A | N/A | N/A |
3/31/2021 | 13,299 | 2,012 | 2,615 | 3,560 | N/A |
12/31/2020 | 12,412 | 1,721 | 3,180 | 3,774 | N/A |
3/31/2020 | 11,227 | 1,192 | 1,495 | 2,015 | N/A |
3/31/2019 | 9,204 | -477 | 566 | 1,339 | N/A |
3/31/2018 | 6,652 | -474 | N/A | 1,058 | N/A |
3/31/2017 | 5,689 | 326 | N/A | 815 | N/A |
3/31/2016 | 5,145 | 266 | N/A | 955 | N/A |
3/31/2015 | 4,222 | 56 | N/A | 639 | N/A |
3/31/2014 | 3,569 | 69 | N/A | 778 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: KIMSDas prognostizierte Gewinnwachstum (24.7% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: KIMSDie Erträge des Unternehmens (24.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (17.9% pro Jahr).
Hohe Wachstumserträge: KIMSEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: KIMSDie Einnahmen des Unternehmens (22.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.5% pro Jahr).
Hohe Wachstumseinnahmen: KIMSDie Einnahmen des Unternehmens (22.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: KIMSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.3%).